<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01845740</url>
  </required_header>
  <id_info>
    <org_study_id>IMMU-115-04</org_study_id>
    <nct_id>NCT01845740</nct_id>
  </id_info>
  <brief_title>Phase Ib Study of SC Milatuzumab in SLE</brief_title>
  <official_title>A Phase Ib Study of Milatuzumab Administered Subcutaneously in Patients With Active Systemic Lupus Erythematosus (SLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunomedics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Immunomedics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Milatuzumab will be given subcutaneously at different dose levels once (depending on the dose
      level) for 4 weeks to determine if milatuzumab helps to control lupus (SLE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Milatuzumab or placebo will be given subcutaneously once weekly for 4 weeks to determine if
      milatuzumab helps to control lupus (SLE). The treatment portion of the study lasts 4 weeks.
      Then patients are followed for disease activity for at least 12 weeks. If patients respond to
      the study drug, they may be eligible for one course of retreatment, again followed by 12
      weeks of follow-up. Patients who showed a response will continue to be followed at timepoints
      up to one year after treatment to assess how long the response lasts.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Safety of the subcutaneously administered milatuzumab will be assessed using laboratory and clinical data comparing baseline lab results and clinical condition to the lab results and clinical condition/adverse events during treatment and follow-up timepoints up to 2 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Efficacy will be assessed using the BILAG scoring model for lupus disease activity and symptoms by comparing baseline BILAG measurements against the BILAG measurements obtained during treatment and during follow-up for up to 2 years.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lupus Erythematosus, Cutaneous</condition>
  <condition>Lupus Erythematosus, Discoid</condition>
  <condition>Lupus Erythematosus, Systemic</condition>
  <condition>Lupus Vasculitis, Central Nervous System</condition>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Milatuzumab SC 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Milatuzumab 250 mg will be administered subcutaneously once weekly for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Milatuzumab 150 mg SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Milatuzumab 150 mg will be administered subcutaneously once weekly for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered subcutaneously once weekly for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>milatuzumab</intervention_name>
    <description>Milatuzumab has been used in clinical trials for multiple myeloma, non-Hodgkin's lymphoma and leukemia in the intravenous dosing form. In this study, milatuzumab is being given subcutaneously in patients with lupus.</description>
    <arm_group_label>Milatuzumab SC 250 mg</arm_group_label>
    <arm_group_label>Milatuzumab 150 mg SC</arm_group_label>
    <other_name>Milatuzumab is a Cd74 targeted humanized monoclonal antibody.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered subcutaneously once weekly for 4 weeks.</description>
    <arm_group_label>Placebo SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥ 18 years old

          -  Signed written informed consent before study entry

          -  Diagnosis of SLE by American College of Rheumatology revised criteria (meets ≥ 4
             criteria)

          -  Positive ANA (titer ≥ 1:80) at study entry

          -  At least 1 BILAG A or 2 BILAG B scores in any organ/body system and ≥ 6 SELENA-SLEDAI
             score

          -  Receiving at least 5.0 mg/day oral prednisone (or equivalent) at stable doses for at
             least 4 weeks prior to study entry

          -  If receiving immunosuppressives or antimalarial agents, at stable doses for at least 4
             weeks prior to study entry

        Exclusion Criteria:

          -  Pregnant or lactating women. Women of childbearing potential must have a negative
             pregnancy test.

          -  Women of childbearing potential and fertile men not practicing or unwilling to
             practice birth control during the study

          -  Rituximab, belimumab, other prior antibody, investigational or experimental therapy
             within 6 months

          -  Allergic to murine, chimeric, humanized or human antibodies

          -  Hematologic abnormalities not attributed to lupus: hemoglobin &lt; 8.0 mg/dL, WBC &lt;
             2000/L, ANC &lt; 1500/L, platelets &lt; 50,000/L,

          -  AST, ALT or alkaline phosphatase &gt; 3 times upper limit of normal and not attributed to
             lupus

          -  Serum creatinine &gt; 2.5 mg/dL, proteinuria &gt; 3.5 g/day

          -  Received live vaccine within 4 weeks

          -  Thrombosis, spontaneous or induced abortion, stillbirth or live birth within 4 weeks

          -  Antiphospholipid antibodies AND a history of thromboembolic events

          -  On oral anticoagulants (not including NSAIDs) within 4 weeks

          -  Active infection with antibiotics within 7 days

          -  Infection requiring hospitalization or herpes zoster treatment within 4 weeks

          -  Long-term infectious diseases (tuberculosis, fungal infections) active within 2 years

          -  Malignancy (except squamous or basal cell carcinoma, cervical CIS) within 3 years
             (unless approved by the medical monitor)

          -  History of recurrent abortions (2 or more)

          -  Known HIV, hepatitis B or C, other immunosuppressive states

          -  Other concurrent medical conditions that, in the investigator's opinion, could affect
             the patient's ability to tolerate or complete the study will not be eligible for the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Wegener, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Immunomedics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather Horne</last_name>
    <phone>973-605-8200</phone>
    <phone_ext>173</phone_ext>
    <email>hhorne@immunomedics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center-Wallace Rheumatic Study Center</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Figeruas</last_name>
      <phone>310-360-9197</phone>
      <email>ffigueras@wallacemedical.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Frölich D, Blassfeld D, Reiter K, Giesecke C, Daridon C, Mei HE, Burmester GR, Goldenberg DM, Salama A, Dörner T. The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression. Arthritis Res Ther. 2012 Mar 9;14(2):R54. doi: 10.1186/ar3767.</citation>
    <PMID>22404985</PMID>
  </reference>
  <reference>
    <citation>Gupta P, Goldenberg DM, Rossi EA, Cardillo TM, Byrd JC, Muthusamy N, Furman RR, Chang CH. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. Blood. 2012 Apr 19;119(16):3767-78. doi: 10.1182/blood-2011-09-381988. Epub 2012 Jan 23.</citation>
    <PMID>22271448</PMID>
  </reference>
  <reference>
    <citation>Alinari L, Mahoney E, Patton J, Zhang X, Huynh L, Earl CT, Mani R, Mao Y, Yu B, Quinion C, Towns WH, Chen CS, Goldenberg DM, Blum KA, Byrd JC, Muthusamy N, Praetorius-Ibba M, Baiocchi RA. FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. Blood. 2011 Dec 22;118(26):6893-903. doi: 10.1182/blood-2011-06-363879. Epub 2011 Oct 31.</citation>
    <PMID>22042694</PMID>
  </reference>
  <reference>
    <citation>Santana JM, Grellier P, Rodier MH, Schrevel J, Teixeira A. Purification and characterization of a new 120 kDa alkaline proteinase of Trypanosoma cruzi. Biochem Biophys Res Commun. 1992 Sep 30;187(3):1466-73.</citation>
    <PMID>1417823</PMID>
  </reference>
  <reference>
    <citation>Alinari L, Yu B, Christian BA, Yan F, Shin J, Lapalombella R, Hertlein E, Lustberg ME, Quinion C, Zhang X, Lozanski G, Muthusamy N, Prætorius-Ibba M, O'Connor OA, Goldenberg DM, Byrd JC, Blum KA, Baiocchi RA. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood. 2011 Apr 28;117(17):4530-41. doi: 10.1182/blood-2010-08-303354. Epub 2011 Jan 12.</citation>
    <PMID>21228331</PMID>
  </reference>
  <reference>
    <citation>Hertlein E, Triantafillou G, Sass EJ, Hessler JD, Zhang X, Jarjoura D, Lucas DM, Muthusamy N, Goldenberg DM, Lee RJ, Byrd JC. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood. 2010 Oct 7;116(14):2554-8. doi: 10.1182/blood-2009-11-253203. Epub 2010 Jun 23.</citation>
    <PMID>20574049</PMID>
  </reference>
  <reference>
    <citation>Berkova Z, Tao RH, Samaniego F. Milatuzumab - a promising new immunotherapeutic agent. Expert Opin Investig Drugs. 2010 Jan;19(1):141-9. doi: 10.1517/13543780903463854. Review.</citation>
    <PMID>19968579</PMID>
  </reference>
  <reference>
    <citation>Stein R, Smith MR, Chen S, Zalath M, Goldenberg DM. Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines. Clin Cancer Res. 2009 Apr 15;15(8):2808-17. doi: 10.1158/1078-0432.CCR-08-1953. Epub 2009 Apr 7.</citation>
    <PMID>19351768</PMID>
  </reference>
  <reference>
    <citation>Mark T, Martin P, Leonard JP, Niesvizky R. Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2009 Jan;18(1):99-104. doi: 10.1517/13543780802636162 . Review.</citation>
    <PMID>19053886</PMID>
  </reference>
  <reference>
    <citation>Stein R, Mattes MJ, Cardillo TM, Hansen HJ, Chang CH, Burton J, Govindan S, Goldenberg DM. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5556s-5563s. Review.</citation>
    <PMID>17875789</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2013</study_first_submitted>
  <study_first_submitted_qc>May 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2013</study_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>systemic lupus erythematoses</keyword>
  <keyword>lupus</keyword>
  <keyword>SLE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
    <mesh_term>Lupus Erythematosus, Cutaneous</mesh_term>
    <mesh_term>Lupus Erythematosus, Discoid</mesh_term>
    <mesh_term>Vasculitis, Central Nervous System</mesh_term>
    <mesh_term>Lupus Vasculitis, Central Nervous System</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

